Skip to main content
. 2019 Jun 17;8(7):38. doi: 10.1038/s41389-019-0147-x

Table 1.

TP53 mutation status, CDKN2A/p16 loss, and EC50 values ± standard error of the mean (SEM) of LY2603618/Rabusertib treatment per cell line

Cell line TP53 mutationa CDKN2A (p16) loss EC50 (µM) LY2603618/ Rabusertib
UM-SCC-22A

g. 13419A>G

g. 14754+1G>T

 Double loss 0.045 ± 0.008
UM-SCC-38 g. 13075G>T Loss 0.073 ± 0.027
VU-SCC-OE g. 11727_14754del Double loss 0.160 ± 0.047
VU-SCC-120

g. 13160/13161 GC>TT

g. 13206G>A

 Double loss 0.322 ± 0.035
UM-SCC-47 – – 0.502 ± 0.001
FaDu g. 14070G>T Loss 0.598 ± 0.071
UT-SCC-45 – – 0.686 ± 0.099
VU-SCC-096 g. 13338A>T Loss 0.751 ± 0.133
UD-SCC-2 – Loss 0.800 ± 0.112
VU-SCC-147 g. 14097T>G – 2.225 ± 0.745

aIARC TP53 Database Download TP53 Somatic R12 Genbank: X54156, published in Martens-de Kemp et al.26